NextWave raises $45 million as new anti-hypertensive hits market
This article was originally published in Scrip
Executive Summary
NextWave Pharmaceuticals, a US specialty pharma, has secured $45 million in a series C financing. The funds will be used to commercialise recently launched NEXICLON XR (clonidine) for the treatment of hypertension, expand the firm's CNS portfolio, and prepare for the introduction of a novel extended-release liquid methylphenidate (NWP06) for attention deficit hyperactivity disorder (ADHD), currently under review by the US FDA.